Build Your Comparison

Side-by-side financial analysis
NAKA logo
NAKA
TALK logo
TALK
OPRX logo
OPRX
DOCS logo
DOCS
VEEV logo
VEEV
JPM logo
JPM
KO logo
KO
Try popular comparisons:

Stock Comparison

NAKA vs TALK vs OPRX vs DOCS vs VEEV vs JPM vs KO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NAKA
Nakamoto Inc.

Financial - Capital Markets

Financial ServicesNASDAQ • US
Market Cap$74M
5Y Perf.-96.5%
TALK
Talkspace, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$871M
5Y Perf.+98.5%
OPRX
OptimizeRx Corporation

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$95M
5Y Perf.-57.9%
DOCS
Doximity, Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$3.82B
5Y Perf.-26.3%
VEEV
Veeva Systems Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$25.15B
5Y Perf.-11.1%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$931.59B
5Y Perf.+64.6%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$344.03B
5Y Perf.+27.0%

NAKA vs TALK vs OPRX vs DOCS vs VEEV vs JPM vs KO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NAKA logoNAKA
TALK logoTALK
OPRX logoOPRX
DOCS logoDOCS
VEEV logoVEEV
JPM logoJPM
KO logoKO
IndustryFinancial - Capital MarketsMedical - Care FacilitiesMedical - Healthcare Information ServicesMedical - Healthcare Information ServicesMedical - Healthcare Information ServicesBanks - DiversifiedBeverages - Non-Alcoholic
Market Cap$74M$871M$95M$3.82B$25.15B$931.59B$344.03B
Revenue (TTM)$4M$238M$107M$645M$3.32B$280.33B$49.28B
Net Income (TTM)$-290M$1M$7M$196M$942M$57.05B$13.70B
Gross Margin-376.0%42.2%69.0%89.1%75.0%60.0%61.7%
Operating Margin-82.2%-1.2%13.6%33.3%28.8%25.9%29.3%
Forward P/E37.0x5.4x14.3x17.1x15.0x24.4x
Total Debt$210M$0.00$26M$10M$96M$942.38B$45.49B
Cash & Equiv.$23M$37M$23M$219M$1.42B$343.34B$10.27B

NAKA vs TALK vs OPRX vs DOCS vs VEEV vs JPM vs KOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NAKA
TALK
OPRX
DOCS
VEEV
JPM
KO
StockMay 24Jun 26Return
Nakamoto Inc. (NAKA)1003.5-96.5%
Talkspace, Inc. (TALK)100198.5+98.5%
OptimizeRx Corporat… (OPRX)10042.1-57.9%
Doximity, Inc. (DOCS)10073.7-26.3%
Veeva Systems Inc. (VEEV)10088.9-11.1%
JPMorgan Chase & Co. (JPM)100164.6+64.6%
The Coca-Cola Compa… (KO)100127.0+27.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: NAKA vs TALK vs OPRX vs DOCS vs VEEV vs JPM vs KO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: TALK and DOCS are tied at the top with 2 categories each (7-stock set) — the right choice depends on your priorities. Doximity, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. OPRX, VEEV, and KO also each lead in at least one category. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
NAKA
Nakamoto Inc.
The Financial Services Pick

NAKA doesn't hold a clear category lead here; it's more of a secondary option in this specific comparison.

Best for: financial services exposure
TALK
Talkspace, Inc.
The Defensive Pick

TALK has the current edge in this matchup, primarily because of its strength in defensive.

  • Beta 0.73, current ratio 6.38x
  • 22.0% revenue growth vs NAKA's -33.0%
  • +82.5% vs NAKA's -99.3%
Best for: defensive
OPRX
OptimizeRx Corporation
The Growth Play

OPRX ranks third and is worth considering specifically for growth exposure.

  • Rev growth 18.8%, EPS growth 124.5%, 3Y rev CAGR 20.6%
  • Lower P/E (5.4x vs 24.4x)
Best for: growth exposure
DOCS
Doximity, Inc.
The Value Pick

DOCS is the #2 pick in this set and the best alternative if valuation efficiency is your priority.

  • PEG 0.27 vs KO's 2.19
  • 30.4% margin vs NAKA's -74.0%
  • 16.5% ROA vs NAKA's -56.5%, ROIC 19.8% vs -42.1%
Best for: valuation efficiency
VEEV
Veeva Systems Inc.
The Defensive Pick

VEEV is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 0.69, Low D/E 1.3%, current ratio 4.89x
  • Beta 0.69 vs NAKA's 2.88, lower leverage
Best for: sleep-well-at-night
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM is the clearest fit if your priority is long-term compounding.

  • 495.3% 10Y total return vs KO's 117.1%
Best for: long-term compounding
KO
The Coca-Cola Company
The Income Pick

KO is the clearest fit if your priority is income & stability.

  • Dividend streak 56 yrs, beta -0.20, yield 2.5%
  • 2.5% yield, 56-year raise streak, vs JPM's 1.8%, (5 stocks pay no dividend)
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthTALK logoTALK22.0% revenue growth vs NAKA's -33.0%
ValueOPRX logoOPRXLower P/E (5.4x vs 24.4x)
Quality / MarginsDOCS logoDOCS30.4% margin vs NAKA's -74.0%
Stability / SafetyVEEV logoVEEVBeta 0.69 vs NAKA's 2.88, lower leverage
DividendsKO logoKO2.5% yield, 56-year raise streak, vs JPM's 1.8%, (5 stocks pay no dividend)
Momentum (1Y)TALK logoTALK+82.5% vs NAKA's -99.3%
Efficiency (ROA)DOCS logoDOCS16.5% ROA vs NAKA's -56.5%, ROIC 19.8% vs -42.1%

NAKA vs TALK vs OPRX vs DOCS vs VEEV vs JPM vs KO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
NAKANakamoto Inc.
FY 2025
Product Retail Sales
100.0%$1,479
TALKTalkspace, Inc.

Segment breakdown not available.

OPRXOptimizeRx Corporation
FY 2025
Other Revenue
100.0%$215,000
DOCSDoximity, Inc.
FY 2026
Subscription
94.3%$608M
Service, Other
5.7%$36M
VEEVVeeva Systems Inc.
FY 2026
Subscription Services Veeva Commercial Cloud
86.9%$1.3B
Professional Services Veeva Commercial Cloud
13.1%$189M
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B

NAKA vs TALK vs OPRX vs DOCS vs VEEV vs JPM vs KO — Financial Metrics

Side-by-side numbers across 7 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLDOCSLAGGINGJPM

Income & Cash Flow (Last 12 Months)

DOCS leads this category, winning 3 of 6 comparable metrics.

JPM is the larger business by revenue, generating $280.3B annually — 71519.7x NAKA's $4M. DOCS is the more profitable business, keeping 30.4% of every revenue dollar as net income compared to NAKA's -74.0%. On growth, NAKA holds the edge at +3.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNAKA logoNAKANakamoto Inc.TALK logoTALKTalkspace, Inc.OPRX logoOPRXOptimizeRx Corpor…DOCS logoDOCSDoximity, Inc.VEEV logoVEEVVeeva Systems Inc.JPM logoJPMJPMorgan Chase & …KO logoKOThe Coca-Cola Com…
RevenueTrailing 12 months$4M$238M$107M$645M$3.3B$280.3B$49.3B
EBITDAEarnings before interest/tax-$320M$2M$19M$227M$1.1B$81.4B$15.5B
Net IncomeAfter-tax profit-$290M$1M$7M$196M$942M$57.0B$13.7B
Free Cash FlowCash after capex-$46M-$6M$14M$215M$518M$100.9B$12.6B
Gross MarginGross profit ÷ Revenue-3.8%+42.2%+69.0%+89.1%+75.0%+60.0%+61.7%
Operating MarginEBIT ÷ Revenue-82.2%-1.2%+13.6%+33.3%+28.8%+25.9%+29.3%
Net MarginNet income ÷ Revenue-74.0%+0.5%+6.4%+30.4%+28.4%+20.4%+27.8%
FCF MarginFCF ÷ Revenue-11.7%-2.7%+13.4%+33.3%+15.6%+36.0%+25.5%
Rev. Growth (YoY)Latest quarter vs prior year+3.6%+18.2%-9.5%+5.1%+16.3%+12.1%
EPS Growth (YoY)Latest quarter vs prior year-88.4%+78.0%-67.7%+14.6%+16.0%+18.2%
DOCS leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

OPRX leads this category, winning 4 of 7 comparable metrics.

At 16.6x trailing earnings, JPM trades at a 87% valuation discount to TALK's 130.0x P/E. Adjusting for growth (PEG ratio), DOCS offers better value at 0.40x vs KO's 2.35x — a lower PEG means you pay less per unit of expected earnings growth.

MetricNAKA logoNAKANakamoto Inc.TALK logoTALKTalkspace, Inc.OPRX logoOPRXOptimizeRx Corpor…DOCS logoDOCSDoximity, Inc.VEEV logoVEEVVeeva Systems Inc.JPM logoJPMJPMorgan Chase & …KO logoKOThe Coca-Cola Com…
Market CapShares × price$74M$871M$95M$3.8B$25.2B$931.6B$344.0B
Enterprise ValueMkt cap + debt − cash$261M$834M$98M$3.6B$23.8B$1.53T$379.3B
Trailing P/EPrice ÷ TTM EPS-0.41x130.00x18.81x20.87x28.47x16.63x26.29x
Forward P/EPrice ÷ next-FY EPS est.36.96x5.39x14.27x17.09x14.98x24.45x
PEG RatioP/E ÷ EPS growth rate0.40x1.57x0.94x2.35x
EV / EBITDAEnterprise value multiple138.33x5.98x16.82x19.95x18.80x25.60x
Price / SalesMarket cap ÷ Revenue40.51x3.81x0.87x5.93x7.87x3.33x7.18x
Price / BookPrice ÷ Book value/share0.09x7.72x0.75x4.28x3.58x2.57x10.06x
Price / FCFMarket cap ÷ FCF5.11x18.15x9.24x64.96x
OPRX leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

DOCS leads this category, winning 4 of 9 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-85 for NAKA. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), OPRX scores 7/9 vs NAKA's 2/9, reflecting strong financial health.

MetricNAKA logoNAKANakamoto Inc.TALK logoTALKTalkspace, Inc.OPRX logoOPRXOptimizeRx Corpor…DOCS logoDOCSDoximity, Inc.VEEV logoVEEVVeeva Systems Inc.JPM logoJPMJPMorgan Chase & …KO logoKOThe Coca-Cola Com…
ROE (TTM)Return on equity-84.8%+1.0%+5.5%+19.4%+13.4%+15.9%+41.1%
ROA (TTM)Return on assets-56.5%+0.9%+4.0%+16.5%+11.0%+1.3%+13.1%
ROICReturn on invested capital-42.1%+3.9%+6.8%+19.8%+12.9%+4.5%+15.8%
ROCEReturn on capital employed-76.2%+2.7%+7.8%+20.7%+13.8%+8.9%+17.3%
Piotroski ScoreFundamental quality 0–92676657
Debt / EquityFinancial leverage0.41x0.20x0.01x0.01x2.60x1.33x
Net DebtTotal debt minus cash$187M-$37M$3M-$209M-$1.3B$599.0B$35.2B
Cash & Equiv.Liquid assets$23M$37M$23M$219M$1.4B$343.3B$10.3B
Total DebtShort + long-term debt$210M$0$26M$10M$96M$942.4B$45.5B
Interest CoverageEBIT ÷ Interest expense-24.72x1.89x2.84x0.74x10.70x
DOCS leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

TALK leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $23,495 today (with dividends reinvested), compared to $351 for NAKA. Over the past 12 months, TALK leads with a +82.5% total return vs NAKA's -99.3%. The 3-year compound annual growth rate (CAGR) favors TALK at 62.1% vs NAKA's -67.3% — a key indicator of consistent wealth creation.

MetricNAKA logoNAKANakamoto Inc.TALK logoTALKTalkspace, Inc.OPRX logoOPRXOptimizeRx Corpor…DOCS logoDOCSDoximity, Inc.VEEV logoVEEVVeeva Systems Inc.JPM logoJPMJPMorgan Chase & …KO logoKOThe Coca-Cola Com…
YTD ReturnYear-to-date-74.0%+48.1%-59.1%-52.8%-29.5%+3.4%+17.2%
1-Year ReturnPast 12 months-99.3%+82.5%-62.1%-65.0%-45.1%+25.9%+17.8%
3-Year ReturnCumulative with dividends-96.5%+326.2%-65.6%-35.5%-23.5%+144.6%+40.2%
5-Year ReturnCumulative with dividends-96.5%-42.2%-90.5%-61.4%-49.3%+135.0%+62.7%
10-Year ReturnCumulative with dividends-96.5%-48.5%+56.8%-61.4%+360.3%+495.3%+117.1%
CAGR (3Y)Annualised 3-year return-67.3%+62.1%-29.9%-13.6%-8.5%+34.7%+11.9%
TALK leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — TALK and KO each lead in 1 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than NAKA's 2.88 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TALK currently trades 99.4% from its 52-week high vs NAKA's 0.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNAKA logoNAKANakamoto Inc.TALK logoTALKTalkspace, Inc.OPRX logoOPRXOptimizeRx Corpor…DOCS logoDOCSDoximity, Inc.VEEV logoVEEVVeeva Systems Inc.JPM logoJPMJPMorgan Chase & …KO logoKOThe Coca-Cola Com…
Beta (5Y)Sensitivity to S&P 5002.88x0.73x2.18x0.75x0.69x0.94x-0.20x
52-Week HighHighest price in past year$679.20$5.23$22.25$76.51$310.50$337.77$84.04
52-Week LowLowest price in past year$0.38$2.22$4.57$17.16$148.05$267.80$65.35
% of 52W HighCurrent price vs 52-week peak+0.6%+99.4%+22.8%+26.7%+49.9%+98.7%+95.1%
RSI (14)Momentum oscillator 0–10037.451.647.347.446.470.950.6
Avg Volume (50D)Average daily shares traded281K1.5M436K3.9M2.3M7.2M13.0M
Evenly matched — TALK and KO each lead in 1 of 2 comparable metrics.

Analyst Outlook

KO leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: NAKA as "Buy", TALK as "Hold", OPRX as "Buy", DOCS as "Hold", VEEV as "Buy", JPM as "Buy", KO as "Buy". Consensus price targets imply 234.6% upside for OPRX (target: $17) vs 1.0% for TALK (target: $5). For income investors, KO offers the higher dividend yield at 2.55% vs JPM's 1.78%.

MetricNAKA logoNAKANakamoto Inc.TALK logoTALKTalkspace, Inc.OPRX logoOPRXOptimizeRx Corpor…DOCS logoDOCSDoximity, Inc.VEEV logoVEEVVeeva Systems Inc.JPM logoJPMJPMorgan Chase & …KO logoKOThe Coca-Cola Com…
Analyst RatingConsensus buy/hold/sellBuyHoldBuyHoldBuyBuyBuy
Price TargetConsensus 12-month target$8.00$5.25$17.00$29.47$235.38$339.75$86.13
# AnalystsCovering analysts2101523436148
Dividend YieldAnnual dividend ÷ price+1.8%+2.5%
Dividend StreakConsecutive years of raises0101556
Dividend / ShareAnnual DPS$5.95$2.04
Buyback YieldShare repurchases ÷ mkt cap+0.4%+2.0%0.0%+11.3%+0.7%+3.7%+0.2%
KO leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

DOCS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). OPRX leads in 1 (Valuation Metrics). 1 tied.

Best OverallDoximity, Inc. (DOCS)Leads 2 of 6 categories
Loading custom metrics...

NAKA vs TALK vs OPRX vs DOCS vs VEEV vs JPM vs KO: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is NAKA or TALK or OPRX or DOCS or VEEV or JPM or KO a better buy right now?

For growth investors, Talkspace, Inc.

(TALK) is the stronger pick with 22. 0% revenue growth year-over-year, versus -33. 0% for Nakamoto Inc. (NAKA). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 6x trailing P/E (15. 0x forward), making it the more compelling value choice. Analysts rate Nakamoto Inc. (NAKA) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — NAKA or TALK or OPRX or DOCS or VEEV or JPM or KO?

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 6x versus Talkspace, Inc. at 130. 0x. On forward P/E, OptimizeRx Corporation is actually cheaper at 5. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Doximity, Inc. wins at 0. 27x versus The Coca-Cola Company's 2. 19x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — NAKA or TALK or OPRX or DOCS or VEEV or JPM or KO?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +135. 0%, compared to -96. 5% for Nakamoto Inc. (NAKA). Over 10 years, the gap is even starker: JPM returned +495. 3% versus NAKA's -96. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — NAKA or TALK or OPRX or DOCS or VEEV or JPM or KO?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Nakamoto Inc. 's 2. 88β — meaning NAKA is approximately -1540% more volatile than KO relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — NAKA or TALK or OPRX or DOCS or VEEV or JPM or KO?

By revenue growth (latest reported year), Talkspace, Inc.

(TALK) is pulling ahead at 22. 0% versus -33. 0% for Nakamoto Inc. (NAKA). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to -1452. 2% for Nakamoto Inc.. Over a 3-year CAGR, TALK leads at 24. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — NAKA or TALK or OPRX or DOCS or VEEV or JPM or KO?

Doximity, Inc.

(DOCS) is the more profitable company, earning 30. 4% net margin versus -28. 7% for Nakamoto Inc. — meaning it keeps 30. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 33. 3% versus -108. 2% for NAKA. At the gross margin level — before operating expenses — DOCS leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is NAKA or TALK or OPRX or DOCS or VEEV or JPM or KO more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Doximity, Inc. (DOCS) is the more undervalued stock at a PEG of 0. 27x versus The Coca-Cola Company's 2. 19x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 5. 4x forward P/E versus 37. 0x for Talkspace, Inc. — 31. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 234. 6% to $17. 00.

08

Which pays a better dividend — NAKA or TALK or OPRX or DOCS or VEEV or JPM or KO?

In this comparison, KO (2.

5% yield), JPM (1. 8% yield) pay a dividend. NAKA, TALK, OPRX, DOCS, VEEV do not pay a meaningful dividend and should not be held primarily for income.

09

Is NAKA or TALK or OPRX or DOCS or VEEV or JPM or KO better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +117. 1% 10Y return). Nakamoto Inc. (NAKA) carries a higher beta of 2. 88 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +117. 1%, NAKA: -96. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between NAKA and TALK and OPRX and DOCS and VEEV and JPM and KO?

These companies operate in different sectors (NAKA (Financial Services) and TALK (Healthcare) and OPRX (Healthcare) and DOCS (Healthcare) and VEEV (Healthcare) and JPM (Financial Services) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NAKA is a small-cap quality compounder stock; TALK is a small-cap high-growth stock; OPRX is a small-cap high-growth stock; DOCS is a small-cap quality compounder stock; VEEV is a mid-cap high-growth stock; JPM is a large-cap deep-value stock; KO is a large-cap quality compounder stock. JPM, KO pay a dividend while NAKA, TALK, OPRX, DOCS, VEEV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.